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Diagnosis of malignant cells in effusions is important for staging procedures and resulting therapeutic decisions. Cytodiagnostics in
effusions is sometimes difficult since reactive mesothelial cells can mimic malignant cells. We used fluorescence in situ hybridisation
(FISH) in single-colour or if appropriate in dual-colour evaluation to detect chromosomal aberrations in effusion cells as markers of
malignancy, to raise the diagnostic yield. Cytologic and FISH evaluations – by using probes representing several chromosomes always
including chromosomes 11 and 17 – were performed in 358 effusion fluids. Cytology was positive for malignancy in 44.4% of all
effusions, whereas FISH was positive in 53.9% (P¼0.0001). The combination of cytology and FISH was diagnostic for malignancy in
60.9% of effusions. Diagnostic superiority of FISH was demonstrated in effusions from breast cancer, lung cancer, pancreatic cancer,
and in effusions from the entire group of gynaecological and gastrointestinal carcinomas. In transudates (effusion protein o2.5gdl
 1),
malignant cells were detectable by cytology, FISH, and combined use of both methods in 18.6, 30, and 37.1% of effusions,
respectively, suggesting that cytologic and molecular analysis should be performed also with transudates. In conclusion, FISH in
combination with conventional cytology is a highly sensitive and specific diagnostic tool for detecting malignant cells in effusions.
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Effusion fluids in cancer patients can arise in the pleural,
pericardial, and peritoneal space. Pathologic accumulation of such
fluid is driven by different forces, among which are ‘paraneoplas-
tic’ effects triggered directly or indirectly by tumour cells. For
example, vascular endothelial growth factor (VEGF) can be
released from tumour cells and it increases the permeability of
peritoneal microvessels and thus contributes to effusion accumu-
lation. On the other hand, removal of VEGF from the peritoneal
cavity has been shown to inhibit ascites formation in ovarian
cancer models (Byrne et al, 2003). About 10–15% of all effu-
sions submitted for pathological analysis are tumour-associated
(Runyon, 1994; Light, 2002), and about 50% of patients develop an
effusion at some time during the course of disease. Clinically,
effusion in tumour disease heralds local disease progression,
relapse or metastasis (Raju and Kardinal, 1981). However, pleural
or ascitic effusions do not always indicate advanced or metastatic
malignant disease, with major clinical consequences. For example,
in lung cancer, a cytologically negative effusion at primary
diagnostic workup usually corresponds with a limited disease
stage, whereas a cytologically positive pleural effusion represents a
UICC/AJCC TNM stage T4 (TNM classification, 1997), translating
into inoperable stage IIIB or IV disease. It is well documented that
the quality of cytodiagnostics regarding tumour-associated effu-
sions primarily depends on the investigator’s experience to
discriminate malignant from reactive effusions. The diagnosis of
malignancy in effusions can be troublesome due to the cellular
composition of effusions. The occurrence of single or clustered
‘activated mesothelial cells’ with morphological features of tumour
cells can mimic malignancy (Koss, 1992). On the other hand, in
effusions tumour cells may appear quite similar to normal cells, for
example, small-cell lung cancer cells and lymphocytes (Chhieng
et al, 2001). Due to these difficulties, cytopathologists traditionally
adopt a rather cautious approach in the diagnosis of malignancy in
effusions. In fact, the sensitivity for the cytological diagnosis of
malignant cells in effusions even in patients with known cancer is
astonishingly low, that is, about 50% (reviewed in Fiegl et al, 2003).
Moreover, the specificity of cytological analysis in effusions does
not reach 100%. Falsely positive results in effusions may occur due
to chronic irritating states of different kinds (Kutty et al, 1981;
Guzman et al, 1992). Thus, new diagnostic approaches are
warranted to enhance the sensitivity and specificity of tumour
cell detection in effusions. We and others used fluorescence in situ
hybridisation (FISH) to sensitively detect tumour cells regularly
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ycharacterised by numeric chromosomal aberrations (Fiegl et al,
2000, 2004; van Oostenbrugge et al, 2000). By identification of
tumour-associated aneuploidy, FISH analysis has been successfully
applied in tumour aspirates, urine, cerebrospinal fluid, cervical
smears, sputum, and effusions (Cajulis et al, 1994; Chen et al, 1995;
Ichikawa et al, 1996; Schenk et al, 1997; Mian et al, 1999; Fiegl et al,
2000, 2004; van Oostenbrugge et al, 2000).
The aims of this study were (1) to determine the percentage of
effusions, which is the first manifestation of malignant disease and
of relapse, (2) to test the diagnostic power of FISH as compared to
cytology in effusions taken from different tumour entities, and (3)
to compare the sensitivity of cytology and FISH in transudates.
The study presented here includes an updated series of 358
effusion specimens, of which various cytological and molecular
aspects have already been previously published (Fiegl et al, 2000,
2004).
MATERIALS AND METHODS
Effusion samples
In all, 403 effusion specimens were collected consecutively from
301 patients with various carcinomas. A total of 110 effusions
originated from patients who had two or three repeated effusion
punctures. Further, 45 of the effusion samples were excluded from
analysis since the time interval between sample collections in an
individual patient was less than 1 month, and, therefore, a
significant alteration of cellular composition could not be
expected. Thus, a total of 358 effusion fluids (198 of pleural, 153
of ascitic origin, five lavage, and two cyst fluids) were subjected to
FISH analysis using centromeric probes for 2–6 chromosomes. An
aliquot of 20–50ml of each effusion was submitted to the
Department of Pathology for cytological evaluation after routine
staining (Giemsa, Papanicolau, or H&E). The first 201 effusions
(series 1; Fiegl et al, 2000) were analysed at the University of
Vienna Medical School between 1994 and 1998, whereas the
remaining 157 effusions (series 2; Fiegl et al, 2004) were analysed
at the University of Innsbruck Medical School between 2001 and
2002. For the definition of cutoffs for malignancy by FISH analysis
(Table 2), cells from 15 and 66 control effusions, derived from
patients with diseases other than cancer, were used in series 1 and
2, respectively.
A detailed description of the progeny of effusions, their
underlying malignancies, and the proportion of effusions occur-
ring as the first manifestation of malignant disease or of relapse is
given in Table 1. All patients had former or present histopatho-
logically or cytologically verified tumours, mostly with distant
metastasis or locally advanced, inoperable disease.
Fluorescence in situ hybridisation analysis
Cells of at least 350ml of effusion fluid (exception: lavages, cyst
fluids, and a few effusions with 2–100ml obtained) were gained by
centrifugation, and, in case of macroscopic blood contamination,
subjected to density gradient separation over Ficoll–Hypaque
(Sigma, St Louis, MO, USA). Pelleted effusion cells were washed in
phosphate-buffered saline, fixed in methanol–acetic acid (3:1,
vv
 1) and stored at  801C. Directly fluorescence-labelled alpha-
satellite DNA probes (SpectrumGreen ([excitation peak of 497nm,
emission peak of 524nm) and SpectrumOrange (559/588nm);
Vysis Inc, Downers Grove, IL, USA) were applied in dual-colour
FISH experiments. The probes used in this study were specific for
the centromeres of chromosomes 7, 8, 11, 12, 17, and 18 for the
first 201 consecutive effusions (Fiegl et al, 2000); subsequently,
only probes representing chromosomes 11 and 17 were used (Fiegl
et al, 2004). The standard protocol followed has been described in
a previous report, with minor modifications (Drach et al, 1995).
Fluorescence microscopy and definition of cutoffs for
aneuploidy
A fluorescence microscope with  60 and  100 planar objectives
and appropriate filter sets was used for FISH signal evaluation and
documentation. All effusion cells in a field except for poly-
nucleated granulocytes, which are easily distinguishable by nuclear
shape, were analysed. The stringent criteria of FISH signal
assessment were applied to avoid overestimation of hyperdiploidy,
which may result from cellular and technical factors (reviewed in
Eastmond et al, 1995). Signal counting was performed by two
investigators, and intraobserver and interobserver counting
variations were evaluated repeatedly. In order to evaluate the
frequencies of aneusomic effusion cells with statistical reliability,
centromeric signals of 100–1000 nuclei were scored, with high-
number cell counting in samples with a low frequency of
aneuploidy (Kibbelaar et al, 1993). When necessary, we used a
two-tiered scoring procedure: (1) in all 358 effusions, scoring of
nuclei in single-colour FISH evaluation was performed, and if
aneusomy above cutoff for any of the tested chromosomes
(Table 2) was present, malignancy could be documented;
otherwise, in step (2), scoring of selected, namely hyperdisomic,
nuclei was performed in dual-colour FISH evaluation, which
allowed for the detection of rare FISH-aneuploid cells (Fiegl et al,
1999). For the analysis of the first 201 effusions (series 1) and the
remaining 157 effusions (series 2), slightly different criteria to
discriminate malignant from reactive effusions by FISH were used.
This was necessary since the first author changed laboratories in
1998 and, therefore, cutoffs for background aneusomy and true,
tumour-associated aneuploidy had to be redefined. In Table 2, the
criteria which allowed diagnosis of malignant cell involvement in
effusion series 1 and 2 are presented, and the diagnostic
specificities as determined in control effusions are indicated. In
series 1, cutoffs (Table 3) were derived from the analysis of a
somewhat limited number of 15 control effusions, whereas the
slightly more stringent cutoffs used in series 2 were derived from
66 control effusions; we concluded that the specificity of FISH
evaluation was at least 97% (Fiegl et al, 2004).
All test effusion specimens were routinely evaluated by cytology
and classified as being benign/reactive or malignant using
Table 1 Origin of effusions, underlying malignancies and number of
effusions representing first manifestation of disease or of relapse
Effusion
Tumour
entity
Patients
(n)
Effusions
(n) A/P/L/C
a
First
manifestation
of disease
First
manifestation
of relapse
Breast 77 104 28/75/0/1 4 24
Lung 60 71 7/64 21 7
Pancreatic 33 34 31/3 1 1
Ovarian 26 29 18/9/1/1 10 2
Hepatoma 17 17 15/2
UPC
a 13 17 14/3 5
Gastric 12 14 13/1 2 1
Colorectal 11 11 7/4
Endometrial 9 11 4/3/4 1 4
Cholangio-cellular 8 9 9/0 1
Renal 8 9 4/5 2
Haematological 9 10 2/8
Mesothelioma 3 4 1/3 1
Cervical 3 3 2/1 0 1
Others 12 15 1/14 2
Sum 301 358 156/195/5/2 46 44
aA¼ascites; P¼pleural effusion; L¼lavage fluid; C¼cyst fluid; UPC¼unknown
primary cancer.
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ygenerally accepted criteria (Koss, 1992). Malignancy was also
assumed when only a few suspicious cells (single or clustered)
were present (Sears and Hajdu, 1987). Cytologic evaluation in all
81 control effusions was positive for malignancy in four cases;
thus, the resulting specificity for cytology was 95%.
Statistical analysis
McNemar’s test was used to compare the two different analytical
methods within the one given sample cohort of 358 effusions
(Dwyer, 1991). SSPS software was used for calculations.
RESULTS
Patients’ characteristics
In total, 358 effusions were derived from 301 patients with
histologically proven tumour disease. The most frequent under-
lying tumour entities were breast, lung, pancreatic, ovarian, and
hepatocellular cancer (Table 1). Included in this series were also a
few patients who suffered previously from a tumour and developed
an effusion of unknown origin later in life. Effusion development
was the primary manifestation of malignancy in 46 out of 301
patients (15.3%). A malignant effusion appeared as the first disease
manifestation in 10 out of 26 cases with ovarian cancer (38.4%)
and in 21 out of 60 cases (35%) with lung cancer. Effusion was the
first and frequently the single sign of relapse in 44 out of 301
patients (14.6%). This was most often noted in patients with breast
cancer (24 out of 67, 35.8%). Detailed frequencies of effusion as the
first sign of disease or relapse according to tumour entities are
listed in Table 1.
Fluorescence in situ hybridisation for detection of tumour-
associated aneuploidy
Fluorescence in situ hybridisation analysis was performed in
single-colour FISH evaluation when aneusomy was present above a
cutoff value, unambiguously discriminating tumour-associated
aneusomy from background ‘physiological’ aneusomy. When
aneusomic cells were rare, evaluation in dual-colour FISH
evaluation was performed aiming at discriminating polyploidy
from aneuploidy originating from tumour cells (Figure 1). The
data presented in this paper represent two compiled series of
effusions analysed in two different laboratories. Slightly different
cutoffs for the diagnosis of true malignancy by single- or dual-
colour FISH were applied (Table 2). The larger series presented
here enabled us to test the diagnostic utility of FISH in different
tumour entities. Fluorescence in situ hybridisation analysis was
diagnostic for malignant cells in 193 out of 358 effusions (53.9%),
whereas cytologic evaluation was positive in 159 out of 358
(44.4%). This difference in favour of FISH was statistically
significant (P¼0.0001; McNemar’s test). Taking the positive
results of cytology and FISH together (cyto&FISH), the overall
diagnostic yield was 60.9% (malignancy in 218 out of 358
effusions). Next, the contribution of FISH to detect malignancy
in different tumour entities and tumour categories was analysed,
and the results are summarised in Table 4. Briefly, FISH was
significantly superior as compared to cytology in effusions from
breast carcinoma, lung carcinoma, and gynaecological malignan-
cies as a whole category. When the sensitivity of overall cyto&FISH
was compared to that of cytology alone, the combined diagnostic
workup yielded a significantly superior sensitivity for effusions
from pancreatic carcinoma and all gastrointestinal tumours
together.
In all, 17 effusions originated from patients who formerly
suffered from malignancy but were free from manifest malignant
disease at the time of puncture or thereafter. These patients had
had hepatoma (n¼8), breast cancer (n¼3), renal, endometrial,
cholangiocellular, bronchial carcinoma (n¼1 each), carcinoma of
the cervix uteri (n¼1), and chronic myelogeneous leukaemia
(n¼1). None of these effusions was classified as malignant by
cytology or FISH; thus, they were viewed as of reactive cause.
Cytology and FISH evaluation in transudates
In the following section, the sensitivity of cytology, FISH, and the
combined evaluation was compared between exsudates and
transudates. Results are presented in Table 5. Two different
definitions to discriminate exsudates from transudates were
applied: a transudate was defined by (i) a protein concentration
of o2.5gdl
 1 (Runyon et al, 1992), (ii) an effusion/serum protein
gradient of o0.5 (Light, 2002).
Table 2 Definition of criteria which enabled the diagnosis of tumour-associated aneuploidy by FISH
a in a two-step microscopic evaluation of effusion
specimens
Step of evaluation
First: single-colour FISH Second: dual-colour FISH Specificity
Effusions (n¼358) Series 1 (n¼201) Malignant, if above the respective cutoff (see
Table 3)
Malignant,i fX20 cells with chromosomal
gain detected, of which 450% aneuploid
100% (based on 15 control
effusions)
Series 2 (n¼157) Malignant,i fX5% of scored nuclei with
chromosomal gain, or X15% monosomic
Malignant,i fX20 cells with chromosomal
gain detected, of which 460% aneuploid
97% (based on 66 control
effusions)
aBetween series 1 and series 2, the cutoffs in single-colour and dual-colour FISH evaluation differed, as indicated in the table. Briefly, in the first step of evaluation, nuclei in an
effusion were evaluated in single-colour evaluation, and, if the percentage of nuclei was above cutoff for any of the evaluated chromosomes, a diagnosis positive for malignant cell
involvement was given. If the diagnosis was negative, the second step of evaluation in dual-colour FISH evaluation followed: upon screening of about 10000–20000 nuclei, only
nuclei with hyperdisomy were recorded; those with concordant signal gain (e.g., 4/4-pattern) were classified as polyploid, whereas those with discordant signal gain (e.g., 3/5-
pattern) were classified as aneuploid. Aneuploidy above cutoff as indicated in the table was diagnostic for malignancy (also detailed in Fiegl et al, 2000, 2004).
Table 3 Cutoff threshold levels for background aneusomy (percentage)
for the six chromosomes examined in series 1 (1994–1998)
Signal number category
13 4 44
Chromosome 7 11.5 0.6 0.7 0.2
Chromosome 8 8.7 0.5 0.9 0.1
Chromosome 11 11.2 0.4 1.2 0.2
Chromosome 12 10.0 1.4 1.0 0.2
Chromosome 17 13.4 0.9 1.0 0.1
Chromosome 18 14.7 0.6 0.7 0.0
The presented cutoffs were determined by evaluation of non-disomy in 15
nonmalignant control effusions, and reflect the mean+3 s.d. percentage of aneusomic
cells within each of four FISH signal categories (see Fiegl et al, 2000).
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concentration was available were diagnosed as transudates
due to a protein concentration o2.5gdl
 1; in these samples,
cytology, FISH, and overall cyto&FISH were diagnostic
for malignancy in 18.6, 30, and 37.1%, respectively. From
100 effusion samples, protein levels from matched serum speci-
mens were available. Out of these 100 effusions, 60 were
transudates, with a protein concentration as determined by
effusion protein/serum protein quotient of o0.5; in these,
cytology, FISH, and cyto&FISH were diagnostic for malignancy
in 35, 40, and 50%, respectively.
DISCUSSION
In this study of patients with tumour-associated effusions, it was
possible to determine the percentage of cases in whom the
appearance of effusion was the first sign of primary disease or the
first sign of relapse (Table 1). In the literature, information on the
frequencies of effusion as the first sign of malignant disease or
relapse is sparse. In our patients with invasive breast cancer,
effusion was the first sign of relapse in 36% of cases. This finding is
in line with results from a previously reported series (Raju and
Kardinal, 1981). Of clinical relevance, the strong association
between ‘new effusion of unclear origin’ and a potentially
underlying tumour disease may urge performing further diagnos-
tic steps, including analysis of effusions with molecular tools (see
below).
To the best of our knowledge, this is the largest series
of effusions in which conventional cytology and a molecular
method such as FISH were compared for the detection
of malignancy. We show that FISH analysis for the detection of
tumour-associated aneuploidy is significantly more sensitive
than routine cytology. In control effusions collected from
patients with nonmalignant diseases, cutoffs were set for
discriminating background signals from true aneuploidy, indicat-
ing the presence of tumour cells. With this reference, a sensitivity
of at least 97% was achieved for FISH analysis. The diagnostic
benefit of FISH was most evident in breast and lung cancer
and in the group of gynaecologic malignancies. Cytology remains
certainly the gold standard for the routine analysis of effusions.
However, taking the positive results of cytology and FISH together
(cyto&FISH), the combination of both methods brought
the highest diagnostic yield (Table 4). Overall, cyto&FISH
was clearly superior to cytology alone in breast, lung, and
pancreatic cancer and in the categories of gynaecologic
and gastrointestinal tumours. There was also a trend favouring
cyto&FISH in ovarian carcinoma. When compared to cytology,
FISH analysis is often complementarily diagnostic and should
be used as second diagnostic step in certain cases with negative
or ambiguous cytology. This may be of clinical practice in patients
with known or suspected cancer. We do not propose FISH or
other laborious molecular techniques as first-line diagnostic
tools in all effusion samples submitted to analysis, due to a low
pre-test probability of detecting malignant cells in many cases and
costs.
Transudates are considered to be tumour cell contaminated in
r5% of cases (Ashchi et al, 1998). Notably, cytology and FISH
enabled us to detect tumour cells even in a significant proportion
of transudates as defined by protein concentration and effusion/
serum protein ratio. There has been intensive debate in the
literature over whether or not effusions classified as transudates
need any further diagnostic evaluation (Ashchi et al, 1998; Castro
et al, 1998; Moltyaner et al, 2000). Our data support the view that,
as is the case with exsudates, cytologic and molecular evaluation is
warranted in transudates as well.
Table 4 Diagnostic sensitivities of cytology, FISH, and the combination of both (cyto&FISH) in the whole series of effusions and major tumour entities
(with X10 effusions per tumour entity available)
Tumour Effusion (n) Sensitivity cytology (%) Sensitivity FISH (%) P Sensitivity Cyto&FISH (%) P
All 358 44.4 53.9 0.0001 60.9 0.0001
Gynaecologic
a 147 54.4 63.9 0.018 72.1 0.0001
Breast 104 50 63.1 0.031 71.2 0.0001
Ovarian 29 65.5 72.4 0.727 82.75 0.063
Endometrial 11 54.4 63.6 1 63.6 1
Gastrointestinal
b 87 28.7 36.8 0.118 41.4 0.001
Pancreatic 34 38.2 52.9 0.125 55.9 0.031
Hepatoma 17 0 5.9 1 5.9 1
Gastric 14 50 64.3 0.625 71.4 0.25
Colorectal 11 18.2 18.2 1 27.3 1
Lung 71 54.9 71.8 0.008 76.1 0.0001
UPC
c 17 35.3 47.1 0.687 58.8 0.125
Haematological
d 10 50 30 0.5 50 1
The P-values indicate significance levels for the comparison of FISH vs cytology (left column) and of cyto&FISH vs cytology (right column).
aGynaecologic tumours: breast
(n¼104), ovarian (29), endometrial (11), and cervical carcinoma (3).
bGastrointestinal tumours: pancreatic (34), hepatocellular (17), gastric (14), colorectal (11), cholangiocellular
(9), and oesophageal carcinoma (2).
cUPC, unknown primary cancer.
dHaematological malignancies: non-Hodgkin’s lymphoma (5), chronic myelogeneous leukaemia (2),
Hodgkin’s lymphoma (2), idiopathic myelofibrosis (1).
Table 5 Diagnostic sensitivity of cytology and FISH (and their combination) in transudates
a
Number of transudates positive for tumour cells (%)
Cytology FISH Cyto&FISH
Definition transudate Protein o2.5 gdl
 1 (n¼70) 13 (18.6) 21 (30) 26 (37.1)
Effusion/serum-protein gradient o0.5 (n¼60) 21 (35) 24 (40) 30 (50)
aTwo different common definitions, as explained in the text.
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of the molecular examinations capable of detecting malignant cells
dispersed in effusions. Others are reverse-transcriptase–polymer-
ase chain reaction and single-nucleotide polymorphism (SNP)
analysis (Yang et al, 1998; Chang et al, 2002; Gru ¨newald et al,
2002). The big advantage of FISH is the direct visualisation
of tumour cells exhibiting numeric chromosomal aberrations
(Figure 1). The diagnostic power of FISH may be further improved
in two ways: first, if the primary tumour is FISH-genotyped
with a panel of FISH probes for different chromosomes as part
of the initial diagnostic work-up, the probe(s) best suited
to indicate tumour-associated aneusomy in an individual case
can be chosen to sensitively detect tumour cell involvement
in effusions taken subsequently. With this procedure, we and
others were able to show by FISH that primary tumours
and synchronous or metachronous locoregional or distant
metastases exhibit nearly identical patterns of numeric chromo-
somal aberrations (Simpson et al, 1996; Fiegl et al, 2000; Fehm et al,
2002). Second, enrichment steps like flow cytometry or immuno-
bead selection can be applied prior to FISH analysis in order to
deplete the reactive cellular background (Feuring-Buske et al,
1999; Sakaguchi et al, 1999).
Diagnosis of malignant cells in effusions or other body fluids
such as lavages, urine, and cerebrospinal fluid is essential for
adequate staging and prognostic evaluation. For example, in lung
cancer the absence or presence of malignant cells in pleural
effusions discriminates limited (e.g., T1) from locally advanced
stages (e.g., T4), with very different consequences for therapeutic
management. It could be decisive, before a planned resection of
lung cancer, to analyse by cytology and FISH an accompanying
effusion or a pleural lavage (Buhr et al, 1997). Improved detection
of pleural metastasis by ‘molecular upstaging’ could prevent
patients with more extensive disease from undergoing surgery. We
demonstrated in this study that FISH can be most useful for
staging procedures in patients with cytologically negative or
unclear effusions. However, conventional cytology in effusions is
to date the only method accepted in the classical UICC/AJCC TNM
classification (Hermanek et al, 1999). Confirmatory prospective
studies are required to demonstrate the clinical benefit of
molecular methods to detect disseminated tumour cells in terms
of disease outcome. Based on our experience, we believe that
molecular diagnostics such as FISH will become indispensable in
initial diagnosis for the diagnostic workup of primary tumour
tissue and other materials (e.g., pleural lavage, bone marrow), and
for restaging during the course of malignant disease.
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